## PFE: Pfizer Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.5% below STRENGTH zone (4.0-10.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($23.72)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 4)

**1. Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching**
- Source: ts2.tech | 20251223T163618 | Somewhat-Bearish | Relevance: 100%
- Pfizer Inc. (PFE) stock is experiencing a complicated end to 2025, balancing its high-yield "value" profile with uncertainties surrounding its post-COVID growth strategy. Recent developments include a safety alert for its hemophilia therapy Hympavzi and the release of its 2026 guidance, which fell short of analyst expectations. The company continues to offer a strong dividend while pursuing pipeline expansion and strategic acquisitions, particularly in the obesity market, to address upcoming patent expirations and rebuild investor confidence in its long-term growth trajectory.

**2. Pfizer (PFE) Valuation Check as Padcev–Keytruda Success and Obesity Deals Recast Its Post‑COVID Growth Story**
- Source: Simply Wall Street | 20251223T001214 | Somewhat-Bullish | Relevance: 100%
- Pfizer recently released strong Phase 3 data for Padcev plus Keytruda in bladder cancer, providing a new catalyst for the company. This development, alongside strategic business acquisitions and pipeline diversification into high-value areas like oncology, immunology, and obesity, is reshaping Pfizer's growth profile after the COVID-19 pandemic. The company is currently considered undervalued with a narrative fair value near $29.08, despite trading below its pre-COVID peak.

**3. Patient dies after taking Pfizer drug for hemophilia**
- Source: Українські Національні Новини | 20251223T174518 | Bearish | Relevance: 100%
- A patient participating in an open-label extension study for Pfizer's hemophilia drug, Hympavzi, died on December 14 after experiencing serious adverse events including stroke and intracranial hemorrhage. Pfizer is gathering more information but currently does not anticipate an impact on patient safety. This incident adds to Pfizer's challenges in the blood disorder treatment field, following previous safety issues and discontinued gene therapy developments.

**4. Patient dies after receiving Pfizer’s hemophilia drug Hympavzi**
- Source: Investing.com | 20251223T150833 | Bearish | Relevance: 100%
- A patient in a long-term study for Pfizer Inc.'s hemophilia drug Hympavzi (marstacimab) died on December 14 after experiencing serious adverse events, including a stroke and brain hemorrhage. The patient, who had hemophilia A with inhibitors, was receiving marstacimab prophylaxis and recombinant factor VIIa for perioperative hemostatic management following minor surgery. Pfizer is now conducting a comprehensive review of the event and has notified regulatory authorities.

**5. Patient dies after receiving Pfizer’s hemophilia drug Hympavzi By Investing.com**
- Source: Investing.com Nigeria | 20251223T150818 | Bearish | Relevance: 100%
- A patient participating in a long-term study for Pfizer Inc.'s hemophilia drug Hympavzi died on December 14 due to a cerebellar infarction and cerebral hemorrhage. The incident occurred while the patient, who had hemophilia A with inhibitors, was receiving marstacimab prophylaxis alongside recombinant factor VIIa for post-surgery hemostatic management. Pfizer is conducting a comprehensive review with an independent committee and has notified regulatory authorities, as such thrombotic events are a known adverse risk for rebalancing therapies like Hympavzi, especially when combined with other clotting agents.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $27 | $28 | -4% |
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.7% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (3 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $141.5B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.3 |
| Current P/E | 8.0 |
| YoY Growth | -3.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.2% to -3.5% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). RSI neutral at 44. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.55% (CS: 19) | Weak |
| RSI_14 | 44.0 | Neutral |
| MACD Histogram | -0.11 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.015x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $24.88
- **Stop Loss:** $23.72 (4.7% risk)
- **Target:** $26.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1034
- **Position Value:** $25,725.92
- **Portfolio %:** 25.73%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*